title: Bisphosphonates for osteoporosis--where do we go from here?
authors.affiliation: Division of Reproductive and Urologic Products, Office of New Drugs, Center for Drug Evaluation and Research, FDA, Silver Spring, MD, USA.
authors.forename: Marcea
authors.initials: M
authors.lastname: Whitaker
authors.forename: Jia
authors.initials: J
authors.lastname: Guo
authors.forename: Theresa
authors.initials: T
authors.lastname: Kehoe
authors.forename: George
authors.initials: G
authors.lastname: Benson
mesh_terms: D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000494:pharmacology / Q000627:therapeutic use*; D004164:Diphosphonates / Q000494:pharmacology / Q000627:therapeutic use*; D050723:Fractures, Bone / Q000453:epidemiology / Q000517:prevention & control*; D006801:Humans; D010024:Osteoporosis / Q000188:drug therapy*; D012306:Risk; D016103:Spinal Fractures / Q000453:epidemiology / Q000517:prevention & control
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates